{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:35:13Z","timestamp":1790447713498,"version":"4.1.0"},"reference-count":51,"publisher":"Becaris Publishing Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            Warfarin and direct-acting oral anticoagulants (DOACs) are widely prescribed to patients with nonvalvular atrial fibrillation (NVAF) to reduce risk of stroke and systemic embolism (SE). This study aimed to assess the cost\u2013effectiveness of apixaban compared with warfarin, dabigatran and rivaroxaban, for patients with NVAF from a US healthcare payer (Medicare) perspective.\n            <jats:bold>Methods:<\/jats:bold>\n            A cohort-level Markov model was developed based on a previously published model, for the US setting, factoring in anticipated price decreases due to market entry of generic drugs. Two retrospective cohort studies in US Medicare patients provided inputs to quantify clinical events in the base case setting and in a scenario analysis. For this study, equal value of life-years (evLYs) and health years in total (HYT) were used. Cost\u2013effectiveness was assessed based on a willingness-to-pay threshold of $100,000 per evLY gained (evLYG) or HYT gained (HYTG).\n            <jats:bold>Results:<\/jats:bold>\n            Apixaban treatment was associated with gains of 2.23, 1.08 and 1.72 evLYs and 2.26, 1.08 and 1.73 HYTs, compared with warfarin, dabigatran and rivaroxaban, respectively. In the base case analysis from a Medicare perspective, apixaban was cost-effective (i.e., value for money) compared with warfarin, dabigatran and rivaroxaban, with corresponding incremental cost\u2013effectiveness ratio (ICER) per evLYG (and HYTG) of $10,501 ($10,350), $7809 ($7769) and $758 ($768), respectively. When a societal perspective was included, and in a scenario analysis using US Medicare data from the Ray\n            <jats:italic>et al.<\/jats:italic>\n            study to quantify treatment effects, apixaban dominated rivaroxaban (i.e., less expensive and more effective) in terms of ICER per evLYG (and HYTG).\n            <jats:bold>Conclusion:<\/jats:bold>\n            Using dynamic pricing assumptions, treatment with apixaban compared with warfarin, dabigatran and rivaroxaban was associated with incremental evLYs and HYT and represents a cost-effective treatment option in patients with NVAF, from a US healthcare payer (Medicare) perspective.\n          <\/jats:p>","DOI":"10.57264\/cer-2024-0163","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T10:57:50Z","timestamp":1732791470000},"source":"Crossref","is-referenced-by-count":11,"title":["US cost\u2013effectiveness analysis of apixaban compared with warfarin, dabigatran and rivaroxaban for nonvalvular atrial fibrillation, focusing on equal value of life years and health years in total"],"prefix":"10.57264","volume":"14","author":[{"given":"Nipun","family":"Atreja","sequence":"first","affiliation":[{"name":"Bristol Myers Squibb Company, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasper","family":"Johannesen","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb Company, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupesh","family":"Subash","sequence":"additional","affiliation":[{"name":"Pfizer Ltd., Tadworth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Bektur","sequence":"additional","affiliation":[{"name":"Health Economics &amp; Outcomes Research Ltd., Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Hagan","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb Company, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dionne M","family":"Hines","sequence":"additional","affiliation":[{"name":"Pfizer Inc., NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iulia","family":"Dunnett","sequence":"additional","affiliation":[{"name":"Health Economics &amp; Outcomes Research Ltd., Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Stawowczyk","sequence":"additional","affiliation":[{"name":"Health Economics &amp; Outcomes Research Ltd., Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"1","key":"e_1_3_8_3_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/CIRCRESAHA.120.316340","article-title":"Epidemiology of atrial fibrillation in the 21st Century: novel methods and new insights","volume":"127","author":"Kornej J","year":"2020","unstructured":"Kornej J, B\u00f6rschel CS, Benjamin EJ, Schnabel RB. Epidemiology of atrial fibrillation in the 21st Century: novel methods and new insights. Circ. Res. 127(1), 4\u201320 (2020).","journal-title":"Circ. Res."},{"issue":"8","key":"e_1_3_8_4_2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"Wolf PA","year":"1991","unstructured":"Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22(8), 983\u2013988 (1991).","journal-title":"Stroke"},{"issue":"2","key":"e_1_3_8_5_2","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/01.STR.32.2.392","article-title":"Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project)","volume":"32","author":"Lamassa M","year":"2001","unstructured":"Lamassa M, Di Carlo A, Pracucci G Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke 32(2), 392\u2013398 (2001).","journal-title":"Stroke"},{"issue":"6","key":"e_1_3_8_6_2","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/01.STR.0000166053.83476.4a","article-title":"Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study","volume":"36","author":"Marini C","year":"2005","unstructured":"Marini C, De Santis F, Sacco S Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 36(6), 1115\u20131119 (2005).","journal-title":"Stroke"},{"key":"e_1_3_8_7_2","unstructured":"Federal Drugs Agency. Apixaban prescribing information. (2021) (Accessed: October 2023) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/202155s034lbl.pdf"},{"key":"e_1_3_8_8_2","unstructured":"Federal Drugs Agency. Dabigatran etexilate prescribing information. (2021) (Accessed: October 2023) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/022512s041lbl.pdf#page=27"},{"key":"e_1_3_8_9_2","unstructured":"Federal Drugs Agency. Edoxaban prescribing information. (2020) (Accessed: October 2023). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/206316s016lbl.pdf#page=35"},{"key":"e_1_3_8_10_2","unstructured":"Federal Drugs Agency. Rivaroxaban prescribing information. (2022) (Accessed: October 2023) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/022406s039 202439s038lbl.pdf#page=77"},{"key":"e_1_3_8_11_2","doi-asserted-by":"crossref","first-page":"j5058","DOI":"10.1136\/bmj.j5058","article-title":"Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis","volume":"359","author":"Lopez-Lopez JA","year":"2017","unstructured":"Lopez-Lopez JA, Sterne JAC, Thom HHZ Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 359, j5058 (2017).","journal-title":"BMJ."},{"issue":"12","key":"e_1_3_8_12_2","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly SJ","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361(12), 1139\u20131151 (2009).","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"e_1_3_8_13_2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel MR","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365(10), 883\u2013891 (2011).","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"e_1_3_8_14_2","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger CB","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365(11), 981\u2013992 (2011).","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"e_1_3_8_15_2","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano RP","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E Edoxaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 369(22), 2093\u20132104 (2013).","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"e_1_3_8_16_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21090","article-title":"Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost\u2013effectiveness analysis","volume":"21","author":"Sterne JA","year":"2017","unstructured":"Sterne JA, Bodalia PN, Bryden PA Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost\u2013effectiveness analysis. Health Technol. Assess. 21(9), 1\u2013386 (2017).","journal-title":"Health Technol. Assess."},{"key":"e_1_3_8_17_2","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond MF","year":"2015","unstructured":"Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press, UK (2015)."},{"issue":"8","key":"e_1_3_8_18_2","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jval.2019.02.009","article-title":"United States valuation of EQ-5D-5L health states using an international protocol","volume":"22","author":"Pickard AS","year":"2019","unstructured":"Pickard AS, Law EH, Jiang R United States valuation of EQ-5D-5L health states using an international protocol. Value Health. 22(8), 931\u2013941 (2019).","journal-title":"Value Health."},{"issue":"10","key":"e_1_3_8_19_2","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s40273-023-01302-6","article-title":"An Alternative Measure of Health for Value Assessment: The Equal Value Life-Year","volume":"41","author":"Campbell JD","year":"2023","unstructured":"Campbell JD, Whittington MD, Pearson SD. An Alternative Measure of Health for Value Assessment: The Equal Value Life-Year. Pharmacoeconomics 41(10), 1175\u20131182 (2023).","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"e_1_3_8_20_2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jval.2019.10.014","article-title":"Health years in total: a new health objective function for cost\u2013effectiveness analysis","volume":"23","author":"Basu A","year":"2020","unstructured":"Basu A, Carlson J, Veenstra D. Health years in total: a new health objective function for cost\u2013effectiveness analysis. Value Health. 23(1), 96\u2013103 (2020).","journal-title":"Value Health."},{"issue":"1","key":"e_1_3_8_21_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1524-4733.2009.00663.x","article-title":"Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report\u2013Part I","volume":"13","author":"Hay JW","year":"2010","unstructured":"Hay JW, Smeeding J, Carroll NV Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report\u2013Part I. Value Health. 13(1), 3\u20137 (2010).","journal-title":"Value Health."},{"issue":"3","key":"e_1_3_8_22_2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40273-022-01230-x","article-title":"incorporating dynamic pricing in cost\u2013effectiveness analysis: are known unknowns valuable?","volume":"41","author":"McQueen RB","year":"2023","unstructured":"McQueen RB, Anderson KE, Levy JF, Carlson JJ. incorporating dynamic pricing in cost\u2013effectiveness analysis: are known unknowns valuable? Pharmacoeconomics 41(3), 321\u2013327 (2023).","journal-title":"Pharmacoeconomics"},{"key":"e_1_3_8_23_2","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/j.jval.2021.04.482","article-title":"PDG34 Do cost\u2013effectiveness analyses account for drug \u201cgenericization\u201d? A literature review and assessment of implications","volume":"24","author":"Podolsky M","year":"2021","unstructured":"Podolsky M, Neumann P, Basu A, Ollendorf D, Cohen J. PDG34 Do cost\u2013effectiveness analyses account for drug \u201cgenericization\u201d? A literature review and assessment of implications. Value Health. 24, S92\u2013S93 (2021).","journal-title":"Value Health."},{"issue":"1","key":"e_1_3_8_24_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau D","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: updated reporting guidance for health economic evaluations. Value Health. 25(1), 3\u20139 (2022).","journal-title":"Value Health."},{"issue":"7","key":"e_1_3_8_25_2","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/heartjnl-2011-300646","article-title":"cost\u2013effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation","volume":"98","author":"Kansal AR","year":"2012","unstructured":"Kansal AR, Sorensen SV, Gani R cost\u2013effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart 98(7), 573\u2013578 (2012).","journal-title":"Heart"},{"key":"e_1_3_8_26_2","unstructured":"Institute for Clinical and Economic Review. 2020\u20132023 Value Assessment Framework. (2020) (Accessed: October 2023) https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_2020_2023_VAF_102220.pdf"},{"key":"e_1_3_8_27_2","unstructured":"The Professional Society for Health Economics and Outcomes Research. Demystifying ICER's Equal Value of Life Years Gained Metric. (2023) (Accessed: 8 September 2023) https:\/\/www.ispor.org\/publications\/journals\/value-outcomes-spotlight\/vos-archives\/issue\/view\/overcoming-vaccine-hesitancy-injecting-trust-in-the-community\/demystifying-icer-s-equal-value-of-life-years-gained-metric"},{"key":"e_1_3_8_28_2","first-page":"26","article-title":"Demystifying ICER's equal value of life-years gained metric","volume":"2021","author":"O'Day K","year":"2021","unstructured":"O'Day K, Mezzio DJ. Demystifying ICER's equal value of life-years gained metric. Value Outcomes Spotlight. 2021, 26\u201328 (2021).","journal-title":"Value Outcomes Spotlight."},{"issue":"5","key":"e_1_3_8_29_2","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.amjmed.2018.12.023","article-title":"Comparative stroke, bleeding, and mortality risks in older medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation","volume":"132","author":"Graham DJ","year":"2019","unstructured":"Graham DJ, Baro E, Zhang R Comparative stroke, bleeding, and mortality risks in older medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation. Am. J. Med. 132(5), 596\u2013604.e11 (2019).","journal-title":"Am. J. Med."},{"key":"e_1_3_8_30_2","unstructured":"Centers for Disease Control and Prevention: National Center for Health Statistics. United States life tables for males. (2020) (Accessed: October 2023) https:\/\/ftp.cdc.gov\/pub\/Health_Statistics\/NCHS\/Publications\/NVSR\/71-01\/Table02.xlsx"},{"key":"e_1_3_8_31_2","unstructured":"Centers for Disease Control and Prevention: National Center for Health Statistics. United States life tables for females. (2020) (Accessed: October 2023) https:\/\/ftp.cdc.gov\/pub\/Health_Statistics\/NCHS\/Publications\/NVSR\/71-01\/Table03.xlsx"},{"issue":"6","key":"e_1_3_8_32_2","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1161\/STROKEAHA.111.000402","article-title":"cost\u2013effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation","volume":"44","author":"Harrington AR","year":"2013","unstructured":"Harrington AR, Armstrong EP, Nolan PE Jr, Malone DC. cost\u2013effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke 44(6), 1676\u20131681 (2013).","journal-title":"Stroke"},{"issue":"13","key":"e_1_3_8_33_2","doi-asserted-by":"crossref","first-page":"e024296","DOI":"10.1161\/JAHA.121.024296","article-title":"Health state utility values in people with stroke: a systematic review and meta-analysis","volume":"11","author":"Joundi RA","year":"2022","unstructured":"Joundi RA, Adekanye J, Leung AA Health state utility values in people with stroke: a systematic review and meta-analysis. J. Am. Heart Assoc. 11(13), e024296 (2022).","journal-title":"J. Am. Heart Assoc."},{"issue":"4","key":"e_1_3_8_34_2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/0272989X06290495","article-title":"Preference-based EQ-5D index scores for chronic conditions in the United States","volume":"26","author":"Sullivan PW","year":"2006","unstructured":"Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med. Decis. Making. 26(4), 410\u2013420 (2006).","journal-title":"Med. Decis. Making."},{"key":"e_1_3_8_35_2","unstructured":"Kind P Hardman G Macran S. UK population norms for EQ-5D. (1999)."},{"issue":"3","key":"e_1_3_8_36_2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1089\/pop.2013.0056","article-title":"The economic burden to medicare of stroke events in atrial fibrillation populations with and without thromboprophylaxis","volume":"17","author":"Patel AA","year":"2014","unstructured":"Patel AA, Ogden K, Veerman M, Mody SH, Nelson WW, Neil N. The economic burden to medicare of stroke events in atrial fibrillation populations with and without thromboprophylaxis. Popul. Health Manag. 17(3), 159\u2013165 (2014).","journal-title":"Popul. Health Manag."},{"issue":"1","key":"e_1_3_8_37_2","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1080\/13696998.2021.1970954","article-title":"The IMPact of untReated nonvalvular atrial fibrillation on short-tErm clinical and economic outcomes in the US Medicare population: the IMPROVE-AF model","volume":"24","author":"Sussman M","year":"2021","unstructured":"Sussman M, Di Fusco M, Tao CY The IMPact of untReated nonvalvular atrial fibrillation on short-tErm clinical and economic outcomes in the US Medicare population: the IMPROVE-AF model. J. Med. Econ. 24(1), 1070\u20131082 (2021).","journal-title":"J. Med. Econ."},{"issue":"24","key":"e_1_3_8_38_2","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1016\/j.jacc.2015.09.084","article-title":"Time to cost\u2013effectiveness following stroke reduction strategies in AF: warfarin versus NOACs versus LAA closure","volume":"66","author":"Reddy VY","year":"2015","unstructured":"Reddy VY, Akehurst RL, Armstrong SO, Amorosi SL, Beard SM, Holmes DR Jr. Time to cost\u2013effectiveness following stroke reduction strategies in AF: warfarin versus NOACs versus LAA closure. J. Am. Coll. Cardiol. 66(24), 2728\u20132739 (2015).","journal-title":"J. Am. Coll. Cardiol."},{"key":"e_1_3_8_39_2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2147\/CEOR.S98888","article-title":"cost\u2013effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US","volume":"8","author":"Miller JD","year":"2016","unstructured":"Miller JD, Ye X, Lenhart GM cost\u2013effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US. Clinicoecon. Outcomes Res. 8, 215\u2013226 (2016).","journal-title":"Clinicoecon. Outcomes Res."},{"issue":"6","key":"e_1_3_8_40_2","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.amjcard.2014.06.015","article-title":"Efficacy and cost\u2013effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups","volume":"114","author":"Clemens A","year":"2014","unstructured":"Clemens A, Peng S, Brand S Efficacy and cost\u2013effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups. Am. J. Cardiol. 114(6), 849\u2013855 (2014).","journal-title":"Am. J. Cardiol."},{"key":"e_1_3_8_41_2","unstructured":"IBM. Micromedex\u00ae RED. BOOK\u00ae. (Accessed: June 2021) https:\/\/www.nlm.nih.gov\/research\/umls\/rxnorm\/sourcereleasedocs\/mmx.html"},{"issue":"5","key":"e_1_3_8_42_2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/13696998.2019.1582058","article-title":"Time-driven activity-based cost analysis for outpatient anticoagulation therapy: direct costs in a primary care setting with optimal performance","volume":"22","author":"Bobade RA","year":"2019","unstructured":"Bobade RA, Helmers RA, Jaeger TM, Odell LJ, Haas DA, Kaplan RS. Time-driven activity-based cost analysis for outpatient anticoagulation therapy: direct costs in a primary care setting with optimal performance. J. Med. Econ. 22(5), 471\u2013477 (2019).","journal-title":"J. Med. Econ."},{"issue":"13","key":"e_1_3_8_43_2","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/CIRCULATIONAHA.113.002601","article-title":"National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation","volume":"129","author":"Dlott JS","year":"2014","unstructured":"Dlott JS, George RA, Huang X National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation. Circulation 129(13), 1407\u20131414 (2014).","journal-title":"Circulation"},{"key":"e_1_3_8_44_2","unstructured":"Data.CMS.gov. CMS Program Statistics \u2013 Medicare Physician Non-Physician Practitioner & Supplier. (2021) (Accessed: October 2023) https:\/\/data.cms.gov\/summary-statistics-on-use-and-payments\/medicare-service-type-reports\/cms-program-statistics-medicare-physician-non-physician-practitioner-supplier"},{"issue":"6","key":"e_1_3_8_45_2","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/1747493019879658","article-title":"Costs of bleeding on long-term antiplatelet treatment without routine co-prescription of proton-pump inhibitors","volume":"16","author":"Luengo-Fernandez R","year":"2021","unstructured":"Luengo-Fernandez R, Li L, Rothwell PM. Costs of bleeding on long-term antiplatelet treatment without routine co-prescription of proton-pump inhibitors. Int. J. Stroke. 16(6), 719\u2013726 (2021).","journal-title":"Int. J. Stroke."},{"key":"e_1_3_8_46_2","unstructured":"Health Information and Quality Authority. Health Technology Assessment (HTA) of a national screening programme for atrial fibrillation in primary care. (2015) (Accessed: December 2023) https:\/\/www.hiqa.ie\/reports-and-publications\/health-technology-assessments\/hta-atrial-fibrillation-screening"},{"key":"e_1_3_8_47_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13561-015-0045-7","article-title":"Statistical models for the analysis of skewed healthcare cost data: a simulation study","volume":"5","author":"Malehi AS","year":"2015","unstructured":"Malehi AS, Pourmotahari F, Angali KA. Statistical models for the analysis of skewed healthcare cost data: a simulation study. Health Econ. Rev. 5, 11 (2015).","journal-title":"Health Econ. Rev."},{"issue":"23","key":"e_1_3_8_48_2","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1001\/jama.2021.21222","article-title":"Association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation","volume":"326","author":"Ray WA","year":"2021","unstructured":"Ray WA, Chung CP, Stein CM Association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation. JAMA 326(23), 2395\u20132404 (2021).","journal-title":"JAMA"},{"issue":"2","key":"e_1_3_8_49_2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/14737167.2020.1798233","article-title":"cost\u2013effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients","volume":"21","author":"Walter E","year":"2021","unstructured":"Walter E, Voit M, Eichhober G. cost\u2013effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients. Expert Rev. Pharmacoecon. Outcomes Res. 21(2), 265\u2013275 (2021).","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"issue":"2","key":"e_1_3_8_50_2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.clinthera.2013.12.011","article-title":"cost\u2013effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation","volume":"36","author":"Lip GY","year":"2014","unstructured":"Lip GY, Kongnakorn T, Phatak H cost\u2013effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. Clin. Ther. 36(2), 192\u2013210 e20 (2014).","journal-title":"Clin. Ther."},{"issue":"6","key":"e_1_3_8_51_2","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/CIRCOUTCOMES.113.000661","article-title":"cost\u2013effectiveness of oral anticoagulants for treatment of atrial fibrillation","volume":"6","author":"Canestaro WJ","year":"2013","unstructured":"Canestaro WJ, Patrick AR, Avorn J cost\u2013effectiveness of oral anticoagulants for treatment of atrial fibrillation. Circ. Cardiovasc. Qual. Outcomes. 6(6), 724\u2013731 (2013).","journal-title":"Circ. Cardiovasc. Qual. Outcomes."},{"key":"e_1_3_8_52_2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.vhri.2022.09.006","article-title":"Oral anticoagulants for stroke prevention in atrial fibrillation: a systematic review of economic evaluations","volume":"33","author":"Goudarzi Z","year":"2023","unstructured":"Goudarzi Z, Ghafari Darab M, Vazin A Oral anticoagulants for stroke prevention in atrial fibrillation: a systematic review of economic evaluations. Value Health Reg. Issues. 33, 99\u2013108 (2023).","journal-title":"Value Health Reg. Issues."},{"key":"e_1_3_8_53_2","unstructured":"Institute for Clinical and Economic Review. Special Assessment to Inform CMS Drug Price Negotiation: Eliquis and Xarelto. 2023."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2024-0163","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T10:36:53Z","timestamp":1734086213000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2024-0163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.57264\/cer-2024-0163"],"URL":"https:\/\/doi.org\/10.57264\/cer-2024-0163","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"article-number":"e240163"}}